Myeloma: Adding Elotuzumab to Bortezomib/Dex May Improve PFS

Share this content:
Myeloma: Adding Elotuzumab to Bortezomib/Dex May Improve PFS
Myeloma: Adding Elotuzumab to Bortezomib/Dex May Improve PFS

The addition of elotuzumab to bortezomib and dexamethasone prolongs progression-free survival without worsening clinical toxicity in patients with relapsed/refractory multiple myeloma, a study published in the journal Blood has shown.1

Elotuzumab is a SLAMF7-directed immunostimulatory antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received 1 to 3 prior therapies. Researchers sought to evaluate the efficacy and safety of bortezomib plus dexamethasone with or without elotuzumab in patients with relapsed/refractory disease.

Continue Reading Below

For the open-label, phase 2 trial, researchers enrolled 152 patients and randomly assigned them 1:1 to receive elotuzumab plus bortezomib and dexamethasone or bortezomib plus dexamethasone.

Results showed that median progression-free survival was 9.7 months with elotuzumab compared with 6.9 months without the immunotherapy (HR, 0.72; 95% CI, 0.59-0.88; P = .09).

Researchers found that among patients homozygous for the high-affinity FcγRIIIa allele, median progression-free survival was 22.3 months with elotuzumab, bortezomib, and dexamethasone vs 9.8 months for elotuzumab-treated patients homozygous for the low-affinity allele.

Overall response rate was 66% with elotuzumab vs 63% with bortezomib and dexamethasone alone. A total of 36% of elotuzumab-treated patients achieved a very good partial response or better compared with 36% of those in the bortezomib-dexamethasone arm.

The study further demonstrated that elotuzumab may reduce the risk of death by 39% vs bortezomib plus dexamethasone alone (HR, 0.61; 70% CI, 0.43-0.85), but this finding is based on early results.

In terms of safety, grade 1 or 2 infusion reactions only occurred in 5% of patients in the elotuzumab group. No other clinically significant adverse events occurred in the elotuzumab arm that did not occur in the bortezomib-dexamethasone arm.


1. Jakubowiak A, Offidani M, Pégourie B, et al. Randomized phase 2 study of elotuzumab plus bortezomib/dexamethasone (Bd) versus Bd for relapsed/refractory multiple myeloma [published online ahead of print April 18, 2016]. Blood. doi:10.1182/blood-2016-01-694604.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs